P11.41.B The Cost of Inpatient Care For Adult Primary Brain Tumour Patients in England. (5th September 2022)

• Record Type: Journal Article
• Authors: Kanso, N; Le Calvez, K; Mauricaite, R; Williams, M
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 2
• Page Start: ii66
• Page End: ii67
• Publication Date: 2022-09-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac174.230
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: Primary brain tumours are rare, but are the cause of the most life-years lost of any cancer. Given their poor prognosis, questions about their treatment and care costs are important especially in publicly-funded healthcare systems. There is currently very little robust data on the cost of care for brain tumour patients. Here we present up-to-date estimations of the direct inpatient care costs of all adult primary brain tumour patients in England, with a specific breakdown of costs attributed to cranial glioblastomas and cranial meningiomas, the commonest primary brain tumours. Material and Methods: GlioCova uses a linked English national cancer data on over 50, 000 adult primary brain tumour patients diagnosed between 2013-2018, with data on secondary healthcare activities three months before diagnosis - the last three months of 2012, and follow-up data after diagnosis - up to the last admission of 2019. We examined inpatient care with a breakdown of costs attributed to different treatment types: neurosurgery, chemotherapy and radiotherapy. We used the NHS HRG4+ Reference Costs Grouper 2017/2018 to assign costs matched from the National Schedule of Reference Costs 2017/2018. We converted all values to 2021 using the Health CPI Index. Results: There were a total of 51, 775 adult primary brain tumour patients diagnosed in England in the 6 year period between 2013 and 2018. 48, 608 of these were admitted to hospital between the last three months of 2012 and the end of 2019, of which we were able to assign costs to 47, 521 patients (98%). Total inpatient costs for the whole brain tumour cohort were over £973 million during the time period (34% attributed to inpatient care for neurosurgery, chemotherapy, and radiotherapy). 14, 691 (31%) of patients were diagnosed with a cranial glioblastoma, and 9, 501 (20%) of patients were diagnosed with a cranial meningioma. Total inpatient costs were £349 million and £163 million for glioblastoma and meningioma respectively, with 34% again devoted to direct treatment costs. Conclusion: The estimated direct inpatient care costs for all 51, 775 primary brain tumour patients diagnosed in England between 2013 and 2018 were nearly £1 billion (£166 million/year cohort), 2/3 of which was not for direct treatment. This does not include outpatient chemotherapy and radiotherapy costs, other outpatient appointments, patient out-of-pocket costs, primary care, social care, or end-of-life care costs. Future work will examine variation in care and costs and extend the analysis to include outpatients. We hope these data will help make an economic argument for improving care for brain tumour patients. More information on GlioCova: https://blogs.imperial.ac.uk/gliocova/about-gliocova/ .